Transarterial Chemoembolization Combined with Microwave Ablation in Elderly Patients with Recurrent Medium or Large Hepatocellular Carcinoma

Chuxiao Zhang,Yuelan Qin,Yangguang Song,Yingying Liu,Xiaodong Zhu

DOI: https://doi.org/10.2147/jhc.s455411

2024-10-22

Journal of Hepatocellular Carcinoma

Abstract:Chuxiao Zhang, Yuelan Qin, Yangguang Song, Yingying Liu, Xiaodong Zhu Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People's Republic of China Correspondence: Xiaodong Zhu, Department of Radiation OncologyGuangxi Medical University Cancer Hospital, No. 71 hedi Road, Nanning, Guangxi, 530021, People's Republic of China, Email Purpose: There are insufficient data about the optimal treatment for older patients with recurring medium or large hepatocellular carcinoma (HCC). The study intended to assess the effect of transcatheter arterial chemoembolization combined with microwave ablation (TACE-MWA) in an elderly cohort through a retrospective analysis. Methods: From 2011 to 2018, a cohort of individuals (age ≥ 70 years) with recurrent HCC tumors ranging from 3.1 cm to 7 cm underwent either a combination treatment of TACE and MWA (n = 43) or surgical intervention (n = 33). Using the Inverse Probability of Treatment Weighting (IPTW) technique, factors of disease-free survival (DFS), overall survival (OS), and rates of major adverse events were analyzed, retrospectively. Results: The group that underwent surgery had a greater history of alcohol use before treatment ( P = 0.001), as well as a higher Barcelona Clinic Liver Cancer (BCLC) stage for the primary tumor before treatment ( P = 0.014) and a higher primary tumor location before treatment ( P = 0.045). The TACE-MWA group had DFS rates of 86.2%, 68.8%, and 60.4% at 1, 3, and 5 years, while the surgery group had rates of 53.0%, 42.2%, and 25.8% at the same time points. In the TACE-MWA treatment group, survival rates at 1 year, 3 years, and 5 years post-treatment were recorded as 93.0%, 80.8%, and 65.7%, respectively, while in the surgery group, they were 62.7%, 46.9%, and 42.6%. In the univariate analysis using IPTW, the type of treatment was found to have a significant correlation with disease progression (hazard ratio [HR] 0.41, 95% CI 0.20– 0.86, P =0.017). IPTW multivariate analysis showed that treatment modality (HR, 0.35; 95% CI, 0.17 to 0.79; P = 0.011) was the only significant prognostic factor for OS. Conclusion: In elderly patients with recurrent 3.1 cm≤ HCC ≤ 7 cm, TACE-WMA was superior to surgery in the respects of DFS and OS. Keywords: elderly patients, hepatocellular carcinoma, transcatheter arterial chemoembolization, microwave ablation, treatment modality Although surgical resection (SR) is often recommended as a curative approach for patients with extremely early or early stage HCC, 1 the recurrence of HCC after hepatectomy remains a serious challenge. 2,3 For patients who cannot undergo additional locoregional treatments, systemic therapy has become an important part of managing the disease, driven by the development of novel therapies, especially immune checkpoint inhibitors (ICIs) and targeted therapies. These treatments offer better outcomes and are more tolerable than previous options. 4–8 In contrast, locoregional therapy, such as Transcatheter Arterial Chemoembolization (TACE), microwave ablation (MWA), radiofrequency ablation (RFA), and percutaneous ethanol injection (PEI), is effective for treating localized HCC, with the exception of repeated hepatic resection. Although improvement of the dose of ethiodized oil reaching the portal veins by the superselective manner, patients still face the risk of recurrence caused by the tumor morphology or vascularity. Researchers found that the pressure within the HCC nodule is decreased from high to sluggish flow after TACE, which causes an almost complete lack of heat loss as a result of this phenomenon, and intact and perhaps even increased portal blood flow in the surrounding tissue can prevent heat diffusion outside the HCC nodule as well. 9 When ablation was performed in HCC nodules after occlusion of their arterial supply, higher tumor response and better local control could be detected in the results of histopathology. Over the course of almost a decade, multiple research studies have indicated that combining TACE with ablation, such as MWA or RFA, offers a notable increase in survival rates for individuals with recurrent HCC tumors that are 7 cm or smaller and have five or fewer lesions, in comparison to using ablation or TACE alone. 10–14 Additionally, these combined methods have shown to be equally as effective as hepatectomy. 15–17 The number of people with age >65 years is rapidly increasing, from 461 million in 2004 to an estimated 2 billion people by 2050, which has greatly new meaning to health and social care, especially remedy for malignant tumors. 18,19 The treatment of recurrent HCC in patients over 65 years of age presents unique chal -Abstract Truncated-

oncology